User:Melis for GenScript/GenScript Biotech proposal

GenScript Biotech, fully known as GenScript Biotech Corporation, usually referred to as simply GenScript, is an American biotech company. It was co-founded in 2

User:Melis for GenScript/GenScript Biotech proposal
GenScript Biotech Corporation
TypePublic
SEHK: 1548
Industry
Founded2002; 24 years ago (2002) in New Jersey, United States
Founders
Headquarters
Piscataway, New Jersey[4]
,
United States
Area served
Worldwide
Key people
Sherry Shao, (rotating CEO)[5]
Services
Revenue$959.5 million[6] (2025)
Number of employees
6,165[6] (2025)
Subsidiaries
  • GenScript Life Science Group[4]
  • ProBio[7]
  • Bestzyme[8]

GenScript Biotech, fully known as GenScript Biotech Corporation, usually referred to as simply GenScript, is an American biotech company. It was co-founded in 2002 in Piscataway, New Jersey by Frank Zhang, Sally Wang, and Larry Wang. The company's operations are divided into life-science services and products, biologics CDMO, and industrial enzymes.

Outside of the United States, GenScript has established presences in China, Singapore, Japan, the United Kingdom, and the Netherlands, among others.[9]

History

GenScript was formed in 2002 in Piscataway, New Jersey.[10] In 2009, the company secured a $15 million investment from KPCB China Fund.[11]

In 2014, the unit Legend Biotech was founded.[12] In 2015, GenScript went public on the SEHK.[13]GenScript fully acquired CustomArray in 2017.[14] In 2020, its subsidiary Probio was launched.[7]

After the COVID-19 pandemic began, GenScript collaborated with Duke-NUS Medical School to develop a way to test for antibodies in a person that could neutralize the coronavirus.[15] On November 6, the cPass test received emergency use authorization from the United States Food and Drug Administration.[16]

GenScript opened a 50,000-square-foot facility near its New Jersey headquarters in 2021 for developing new vaccines. Their cell and gene therapy manufacturing facility became the company's first automated plant in the country.[4] In 2022, it opened a protein and gene manufacturing facility in Singapore.[17]

In May 2024, the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party asked the Federal Bureau of Investigation (FBI) and Director of National Intelligence for a briefing on whether the Chinese government had any undue influence over GenScript and its units, Bestzyme, Legend Biotech, and ProBio.[18][19] Consequently, GenScript's stock fell on the news. A statement from GenScript denied the connection and said the company was not under any government's control.[20]

Operations

GenScript is headquartered in Piscataway, New Jersey.[4] It established presences in the United States, China, Singapore, Japan, the United Kingdom, and the Netherlands, among others.[9]

GenScript's operations are divided into life-science services and products, biologics CDMO, and industrial enzymes.[21]

The company was founded by Frank Zhang,[1] Sally Wang,[2] and Larry Wang.[3] As of 2026, leadership included Robin Meng, chairman;[22] Sherry Shao, rotating CEO;[5] and Ray Chen, Life Science Group president.[4] Its scientific advisory board includes George Church, Carl June, and David R. Liu, as of 2026.[23]

GenScript has operations in over 100 countries and over 250,000 customers, as of 2025. That year, its revenue was $959.5 million and it had over 6,165 employees.[24]

Subsidiaries

The company's main subsidiaries include the biologics CDMO named ProBio (launched 2020),[7][25] and industrial enzymes producer Bestzyme (launched 2013).[18][26]

In 2024, ProBio opened a manufacturing facility in Hopewell, New Jersey. The year prior, it had raised $224 million in its third fundraising round in two years.[7]

GenScript's shares of Legend Biotech fell in 2024 to 47.6%, causing the company to lose its status as majority shareholder.[27]

Legend Biotech

Legend Biotech was founded in 2014.[12] Legend Biotech was later listed on the NASDAQ under the symbol "LEGN".[28]

In 2017, the Chinese government accepted Legend's application for running clinical trials for its blood cancer treatment,[29] with its IND application approved by the CFDA.[30] In the same year, Legend entered into a collaboration agreement with Janssen Biotech to share chimeric antigen receptor (CAR-T) treatments in the US and China.[12][31]

In 2022, Carvykti, a CAR-T cell therapy developed by Janssen Biotech and Legend Biotech,[32] was approved by the US FDA for the treatment of multiple myeloma in adult patients.[33]

In November 2023, Legend Biotech and Novartis signed an out-license deal to develop and manufacture Legend's CAR-T therapies. Novartis will pay the New-Jersey–based biotech $100 million upfront.[27]

Legend Biotech is no longer a subsidiary of GenScript and the latter is no longer majority shareholder as of 2024.[5]

Production

GenScript had more than 600,000 gene synthesis projects by 2026. It manufactures DNA fragments for use in synthetic biology.[4]

GenScript has labs and factories in New Jersey, Seattle, Nanjing, Zhenjiang, Singapore and Netherlands.[34]

Research

GenScript reported in August 2017 early results for its experimental gene therapy on an aggressive form of blood cancer. In May of the following year, the FDA approved its testing on Americans, the first Chinese-developed gene therapy to receive approval.[12] China’s Center for Drug Evaluation accepted GenScript's clinical trial application in December 2017 for its drug to treat multiple myeloma.[35]

GenScript provides its clients with customized synthetic genes and proteins for research purposes.[35] This includes genes and proteins which allowed scientists in 2022 to develop research variants of COVID-19.[36]

References

  1. ^ a b Feng, Venus; Lee, Yoojung (31 May 2018). "Road to China Drug Riches Runs Through the Bronx, New Jersey". Bloomberg. Retrieved 8 January 2026.
  2. ^ a b Chen, I-Chun (9 November 2020). "Legend Biotech names Huang permanent CEO, Wang chairwoman". New York Business Journal. Retrieved 8 January 2026.
  3. ^ a b "RESIGNATION OF ROTATING CHIEF EXECUTIVE OFFICER" (PDF). hkexnews.hk. GenScript. Retrieved 8 January 2026.
  4. ^ a b c d e f Keenan, Joseph (2 November 2021). "GenScript embraces automation at its first cell, gene therapy manufacturing US site". Fierce Pharma. Retrieved 8 January 2026.
  5. ^ a b c Dunleavy, Kevin (11 November 2024). "GenScript sets up operations and logistics center in Australia". Fierce Pharma. Retrieved 8 January 2026.
  6. ^ a b "Annual Results Announcement For The Year Ended December 31, 2025" (PDF). GenScript. Retrieved 14 April 2026.
  7. ^ a b c d Keenan, Joseph (26 June 2024). "GenScript's ProBio CDMO arm debuts new gene therapy production plant". Fierce Pharma. Retrieved 8 January 2026.
  8. ^ "Annual Results Announcement For The Year Ended December 31, 2024" (PDF). hkexnews.hk. GenScript. Retrieved 8 January 2026.
  9. ^ a b "GenScript Launches A Protein Manufacturing Facility In Singapore". Lianhe Zaobao. Economic Development Board. January 10, 2023.
  10. ^ Venus Feng and Yoojung Lee (May 31, 2018). "Road to Chinese Pharma Riches Runs Through the Bronx, New Jersey". Bloomberg News.
  11. ^ Jonathan Shieber (July 17, 2009). "Kleiner Perkins' Former Front Man In China Starts Fresh". The Wall Street Journal.
  12. ^ a b c d Preetika, Rana (August 5, 2018). "How China Is Evolving From a Maker of Copycat Medicines Into a Producer of Complex Drugs". The Wall Street Journal.
  13. ^ Eric Ng (December 22, 2017). "GenScript's shares jump by a third on US$350m Johnson & Johnson unit tie-up". South China Morning Post.
  14. ^ Idrus, Amirah Al (27 December 2017). "GenScript boosts synthetic biology with CustomArray buy | Fierce Biotech". Fierce Biotech. Retrieved 28 January 2026.
  15. ^ Timothy Goh (February 10, 2022). "GenScript's manufacturing facility boosts S'pore's role in fight against pandemic". The Straits Times.
  16. ^ Liu, Angus (23 November 2020). "GenScript, Legend Biotech founder arrested in China for suspected smuggling". Fierce Pharma. Retrieved 8 January 2026.
  17. ^ Timothy Goh (February 10, 2022). "GenScript's manufacturing facility boosts S'pore's role in fight against pandemic". The Straits Times.
  18. ^ a b Freifeld, Karen (May 31, 2024). "US lawmakers ask FBI for briefing on GenScript Biotech's links to China". Reuters. Retrieved May 31, 2024.
  19. ^ "Moolenaar, Krishnamoorthi Request FBI & DNI Briefing on Chinese Communist Party-Linked Biotech Firm". Select Committee on the CCP. 2024-05-31. Retrieved 2024-06-02.
  20. ^ Qin, Sherry (June 3, 2024). "GenScript Biotech Shares Drop After U.S. Lawmakers Scrutinize Chinese Ties". The Wall Street Journal. Retrieved 2024-06-04.
  21. ^ Dutton, Gail (6 March 2019). "A Genetic Gold Rush Requires Biomolecular Tools". GEN - Genetic Engineering and Biotechnology News. Retrieved 11 February 2026.
  22. ^ "Meng Jiange "Robin" Bloomberg". Bloomberg. Bloomberg. Retrieved 9 April 2026.
  23. ^ "Advisory Board". www.genscript.com. GenScript. Retrieved 11 February 2026.
  24. ^ "Annual Results Announcement For The Year Ended December 31, 2025" (PDF). hkexnews.hk. GenScript. Retrieved 9 April 2026.
  25. ^ Liu, Angus (20 January 2023). "China's reimbursement talks, Sun, GenScript—Fierce Pharma Asia". Fierce Pharma. Retrieved 11 February 2026.
  26. ^ "About Us". Bbestzyme. Bbestzyme. Retrieved 9 April 2026.
  27. ^ a b Liu, Angus (23 October 2024). "Legend sheds GenScript as its majority shareholder". Fierce Pharma. Retrieved 28 January 2026. Cite error: The named reference "Liu 2024" was defined multiple times with different content (see the help page).
  28. ^ Shen, Lucinda (June 5, 2020). "ZoomInfo raises nearly $1 billion in its IPO". Fortune.
  29. ^ Wei, Jianshu; Guo, Yelei; Wang, Yao; Wu, Zhiqiang; Bo, Jian; Zhang, Bin; Zhu, Jun; Han, Weidong (April 2021). "Clinical development of CAR T cell therapy in China: 2020 update". Cellular & Molecular Immunology. 18 (4): 792–804. doi:10.1038/s41423-020-00555-x. PMC 8115146. PMID 32999455.
  30. ^ Wei, Jianshu; Guo, Yelei; Wang, Yao; Wu, Zhiqiang; Bo, Jian; Zhang, Bin; Zhu, Jun; Han, Weidong (April 2021). "Clinical development of CAR T cell therapy in China: 2020 update". Cellular & Molecular Immunology. 18 (4): 792–804. doi:10.1038/s41423-020-00555-x. PMC 8115146. PMID 32999455.
  31. ^ Ballard, Will (October 10, 2019). "Chinese biotech: from copycat to innovator". Financial Times. ISSN 0307-1766.
  32. ^ Dede Williams (January 25, 2023). "GenScript Raises $224 Million in Fresh Capital". CHEManager. Archived from the original on June 10, 2023.
  33. ^ Loftus, Peter (February 28, 2022). "FDA Approves Cell-Based Multiple Myeloma Therapy Discovered in China". The Wall Street Journal.
  34. ^ "2025 Annual Results". GenScript. March 2026. Retrieved 14 April 2026.
  35. ^ a b "In Race for Blood Cancer Therapy, a Chinese Biotech Firm Surges 500%". Bloomberg. February 13, 2018. Retrieved 28 January 2026.
  36. ^ Timothy Goh (February 10, 2022). "GenScript's manufacturing facility boosts S'pore's role in fight against pandemic". The Straits Times.
  • No URL found. Please specify a URL here or add one to Wikidata.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.